Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 4:40 PM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

266 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT, Inc.

Chief Executive Officer, President and Director
Age: 45
Total Annual Compensation: $332.4K
Chief Financial Officer and Principal Accounting Officer
Age: 57
Total Annual Compensation: $202.8K
Chief Operating Officer and Senior Vice President
Age: 53
Total Annual Compensation: $290.2K
Compensation as of Fiscal Year 2014.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2015 and Fiscal Year 2016

Intersect ENT, Inc. provided revenue guidance for the fourth quarter and year ended December 31, 2015 and year 2016. The company anticipates revenue for the fourth quarter of 2015 in the range of $18.6 to $18.8 million, compared to $13.4 million for the fourth quarter of 2014. The company anticipates revenue for the full year 2015 of approximately $61.4 to $61.6 million, compared to $38.6 million for 2014. For the year 2016, the company expects significant revenue growth in 2016 and forecasts revenue to be between $78 and $80 million.

Intersect ENT, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 01:30 PM

Intersect ENT, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 01:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer, President and Director.

Intersect ENT, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-01-2015 09:30 AM

Intersect ENT, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-01-2015 09:30 AM. Venue: Lotte New York Palace, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Virologix Corp. United States
Dignify Therapeutics LLC United States
OncoHoldings, Inc. United States
Iroko Pharmaceuticals, LLC United States
Bio-Origyn, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.